Financial Results for the
First Nine Months of Fiscal Year
Ending December 2023
I Summary Information | P. 1 | |
① | Financial Results | P. 1 |
② | Financial Conditions | P. 1 |
③ | Capital Expenditures | P. 1 |
④ | Depreciation/Amortization | P. 1 |
II Financial Results for the First Nine Months of FY2023 | P. 2 | |
① | Statement of Income | P. 2 |
② | Sales of Products | P. 4 |
③ | Research and Development | P. 5 |
III Financial Forecasts for the FY2023 | P. 6 | |
① | Statement of Income | P. 6 |
② | Sales of Products | P. 8 |
※ This material is prepared based on Japan GAAP.
※ Amounts are rounded down to the nearest million yen.
※ The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein.
Torii will not necessarily revise this material regardless of any new information, future events or other results.
October 31, 2023
TORII PHARMACEUTICAL CO., LTD.
I Summary Information
The forecasts for the FY2023 have been changed from the previous forecasts announced at the first six months of FY2023 financial results announcement on July 31, 2023.
- R&D expenses fluctuate significantly due to aggressive business investments for medium-/long-term growth. For this reason, Torii sets operating income before deduction of R&D expenses as a numerical income indicator in the medium-term management plan.
① Financial Results
FY2022 | FY2023 | Change | ||||
(Millions of Yen) | First nine | First nine | Change | |||
(%) | ||||||
months | months | |||||
A | B | B-A | (B-A)/A | |||
Net sales | 35,315 | 39,132 | 3,817 | 10.8 | ||
Operating income | 4,066 | 3,211 | (855) | (21.0) | ||
Ordinary income | 3,918 | 3,315 | (602) | (15.4) | ||
Net income | 2,856 | 2,368 | (487) | (17.1) | ||
(Reference) | ||||||
R&D expenses | 1,089 | 2,811 | 1,722 | 158.1 | ||
Operating income before | ※ | 5,155 | 6,022 | 867 | 16.8 | |
deduction of R&D expenses | ||||||
Earnings per share | (¥) | 101.66 | 84.27 | (17.39) | ||
(EPS) | ||||||
Return on equity | (%) | 2.4 | 2.0 | (0.4) | ||
(ROE) | ||||||
Ratio of ordinary income | (%) | 3.0 | 2.5 | (0.5) | ||
to total assets | ||||||
Ratio of operating income | (%) | 11.5 | 8.2 | (3.3) | ||
to net sales | ||||||
Return on assets | (%) | 2.2 | 1.8 | (0.4) | ||
(ROA) | ||||||
② Financial Conditions | ||||||
(Millions of Yen) | December 31, | September 30, | Change | Change | ||
2022 | 2023 | (%) | ||||
A | B | B-A | (B-A)/A | |||
Total assets | 133,689 | 132,181 | (1,507) | (1.1) | ||
Total equity | 119,224 | 118,595 | (629) | (0.5) | ||
Equity ratio | (%) | 89.2 | 89.7 | 0.5 | ||
Book value per share (BPS) | (¥) | 4,243.08 | 4,219.67 | (23.41) | ||
③ Capital Expenditures | ||||||
FY2022 | FY2023 | Change | ||||
(Millions of Yen) | First nine | First nine | Change | |||
(%) | ||||||
months | months | |||||
A | B | B-A | (B-A)/A | |||
Capital expenditures | 612 | 147 | (464) | (75.9) | ||
PP&E | 452 | 118 | (333) | (73.8) | ||
Intangible assets | 159 | 28 | (131) | (82.1) | ||
④ Depreciation/Amortization | ||||||
FY2022 | FY2023 | Change | ||||
(Millions of Yen) | First nine | First nine | Change | |||
(%) | ||||||
months | months | |||||
A | B | B-A | (B-A)/A | |||
Depreciation and amortization | 342 | 338 | (3) | (1.1) | ||
of intangible assets | ||||||
Amortization of long-term | 592 | 502 | (89) | (15.2) | ||
prepaid expenses | ||||||
FY2022 | FY2023 | Progress | |
Full year | Revised forecast | ratio (%) | |
C | B/C | ||
48,896 | 54,000 | 72.5 | |
5,540 | 4,500 | 71.4 | |
5,537 | 4,700 | 70.5 | |
3,944 | 3,400 | 69.7 | |
1,661 | 3,600 | 78.1 | |
7,201 | 8,100 | 74.4 | |
140.39 | 120.99 | ||
3.3 | |||
4.2 | |||
11.3 | |||
3.0 | |||
FY2022 | FY2023 |
Full year | Revised forecast |
662 | 250 |
504 | 180 |
158 | 70 |
FY2022 | FY2023 |
Full year | Revised forecast |
454 | 460 |
767 | 670 |
-1-
II Financial Results for the First Nine Months of FY2023
The forecasts for the FY2023 have been changed from the previous forecasts announced at the first six months of FY2023 financial results announcement on July 31, 2023.
- R&D expenses fluctuate significantly due to aggressive business investments for medium-/long-term growth. For this reason, Torii sets operating income before deduction of R&D expenses as a numerical income indicator in the medium-term management plan.
- Statement of Income
(Millions of Yen) | FY2022 | FY2023 | Change | Change | FY2023 | Progress | ||
First nine months | First nine months | (%) | Revised forecast | ratio (%) | ||||
A | B | B-A | (B-A)/A | C | B/C | |||
Net sales | 35,315 | 39,132 | 3,817 | 10.8 | 54,000 | 72.5 | ||
Sales of products | 35,055 | 38,904 | 3,849 | 11.0 | 53,700 | 72.4 | ||
Renal disease and hemodialysis | 8,756 | 8,602 | (154) | (1.8) | 11,970 | 71.9 | ||
Skin disease | 9,107 | 10,347 | 1,239 | 13.6 | 13,980 | 74.0 | ||
Allergens | 13,077 | 15,290 | 2,212 | 16.9 | 21,440 | 71.3 | ||
Other | 4,113 | 4,665 | 552 | 13.4 | 6,310 | 73.9 | ||
Other sales | 260 | 227 | (32) | (12.5) | 300 | 75.9 | ||
Cost of sales | 18,394 | 21,098 | 2,703 | 14.7 | 29,300 | 72.0 | ||
Cost of products sold | 18,355 | 21,057 | 2,702 | 14.7 | ||||
Other cost | 39 | 40 | 0 | 2.4 | ||||
Gross profit | 16,920 | 18,034 | 1,114 | 6.6 | 24,700 | 73.0 | ||
Selling, general and | 12,854 | 14,823 | 1,969 | 15.3 | 20,200 | 73.4 | ||
administrative expenses | ||||||||
R&D expenses | 1,089 | 2,811 | 1,722 | 158.1 | 3,600 | 78.1 | ||
Others | 11,765 | 12,012 | 246 | 2.1 | 16,600 | 72.4 | ||
Operating income | 4,066 | 3,211 | (855) | (21.0) | 4,500 | 71.4 | ||
Operating income before | ※ | 5,155 | 6,022 | 867 | 16.8 | 8,100 | 74.4 | |
deduction of R&D expenses | ||||||||
Non-operating income and expenses | (147) | 104 | 252 | |||||
Ordinary income | 3,918 | 3,315 | (602) | (15.4) | 4,700 | 70.5 | ||
Extraordinary income and loss | 187 | (2) | (189) | |||||
Income before income taxes | 4,105 | 3,312 | (792) | (19.3) | ||||
Income taxes | 1,249 | 944 | (304) | |||||
Net income | 2,856 | 2,368 | (487) | (17.1) | 3,400 | 69.7 | ||
(Reference) Ratio to net sales | ||||||||
(%) | FY2022 | FY2023 | Change | |||||
First nine months | First nine months | |||||||
A | B | B-A | ||||||
Cost of sales | 52.1 | 53.9 | 1.8 | |||||
SG&A | 36.4 | 37.9 | 1.5 | |||||
R&D expenses | 3.1 | 7.2 | 4.1 | |||||
Operating income | 11.5 | 8.2 | (3.3) | |||||
Operating income before | ※ | 14.6 | 15.4 | 0.8 | ||||
deduction of R&D expenses | ||||||||
Ordinary income | 11.1 | 8.5 | (2.6) | |||||
Net income | 8.1 | 6.1 | (2.0) |
-2-
【Factors in increase/decrease compared with the same term of the last fiscal year】
Operating income (¥3,211 million : Decrease ¥855 million year-on-year)
- Increased sales and decreased profits due to increased R&D expenses and cost of sales, despite increased sales of Allergens and CORECTIM
(Millions of yen)
8,000
6,000
4,000
2,000
0
+3,817
4,066
(2,703)
(1,722)
(246)
3,211
FY2022 | Net sales | Cost of sales | R&D expenses | Others | FY2023 |
First nine months | First nine months |
Major factors in increase/decrease (Rounded down to the nearest 0.1 billion yen)
Net sales | Renal disease | : | Decrease ¥0.1 billion in sales | REMITCH Decrease ¥0.6 billion (impact of generic drugs and drug price |
and hemodialysis | revisions),KAYEXALATE decrease ¥0.1 billion(drug price revisions),Riona Increase ¥0.3 | |||
Increase ¥1.2 billion in sales | billion ,ENAROY Increase ¥0.2 billion(increase in sales quantity) | |||
Skin disease | : | CORECTIM Increase ¥1.4 billion, ANTEBATE Increase ¥0.2 billion(increase in sales | ||
quantity),ZEFNART Decrease ¥0.1billion(decrease in sales quantity) | ||||
Allergens | : | Increase ¥2.2 billion in sales | CEDARCURE Increase ¥1.2 billion, MITICURE Increase ¥1.0 billion (increase in sales | |
quantity) | ||||
Other | : | Increase ¥0.5 billion in sales | BIO-THREE Increase ¥0.4 billion, ORLADEYO Increase ¥0.1 billion (increase in sales | |
quantity) | ||||
Cost of sales | : Increase in sales quantity | |||
Increase in purchasing unit price | ||||
Increase due to the effect of foreign exchange rates | ||||
R&D expenses | : Increase due to upfront licensing fees for license agreement with Nogra Pharma Limited | |||
Increase in clinical study expenses(TO-208) | ||||
Others | : Increase in sales-linked expenses | |||
Increase in expenses for operating activities | ||||
Payment of one-time special allowance to employees (inflation allowance) | ||||
Decrease in contract MR |
Ordinary income (¥3,315 million : Decrease ¥602 million year-on-year)
Non-operating income : Increase in interest on securities due to increase in marketable securities and investment | +¥101 million | |
securities | ||
(FY2022) | Non-operating expenses:Cancellation penalty of a manufacturing contract | ¥140 million |
Net income (¥2,368 million : Decrease ¥487 million year-on-year) | ||
(FY2022) | Extraordinary income:Gain on sales of investment securities due to reduction of policy shareholdings | ¥187 million |
(Reference)
Operating income before deduction of R&D expenses (¥6,022 million : Increase ¥867 million year-on-year)
(Millions of yen)
10,000
7,500
5,000
(2,703)
+3,817
(246)
2,500
0
5,155
6,022
FY2022 | Net sales | Cost of sales | Others | FY2023 |
First nine months | First nine months |
-3-
② Sales of Products
(Millions of Yen) | FY2022 | FY2023 | Change | Change (%) |
First nine months | First nine months | |||
A | B | B-A | (B-A)/A | |
Sales of Products | 35,055 | 38,904 | 3,849 | 11.0 | |||
[Renal disease and hemodialysis] | |||||||
Riona | 5,037 | 5,403 | 366 | 7.3 | |||
Agent for hyperphosphatemia, Iron-deficiency anemia | |||||||
REMITCH | 2,613 | 2,011 | (602) | (23.1) | |||
Oral anti-pruritus agent | |||||||
KAYEXALATE | ※ | 914 | 780 | (133) | (14.6) | ||
Agent for hyperkalemia | |||||||
Others | 191 | 406 | 215 | 112.7 | |||
Total | 8,756 | 8,602 | (154) | (1.8) | |||
[Skin disease] | |||||||
CORECTIM | 3,945 | 5,392 | 1,447 | 36.7 | |||
Topical Janus kinase (JAK) inhibitor | |||||||
ANTEBATE | ※ | 2,959 | 3,201 | 242 | 8.2 | ||
Topical corticosteroid | |||||||
LOCOID | ※ | 1,103 | 1,065 | (38) | (3.5) | ||
Topical corticosteroid | |||||||
ZEFNART | 863 | 687 | (175) | (20.3) | |||
Topical antifungal agent | |||||||
Others | 236 | (0) | (237) | - | |||
Total | 9,107 | 10,347 | 1,239 | 13.6 | |||
[Allergens] | |||||||
CEDARCURE | ※ | 6,757 | 7,963 | 1,205 | 17.8 | ||
Japanese cedar pollinosis (Allergen Immunotherapy) | |||||||
MITICURE | ※ | 6,171 | 7,189 | 1,017 | 16.5 | ||
House dust mite allergy (Allergen Immunotherapy) | |||||||
Others | 147 | 137 | (10) | (6.9) | |||
Total | 13,077 | 15,290 | 2,212 | 16.9 | |||
[Other] | |||||||
BIO-THREE | 2,423 | 2,881 | 457 | 18.9 | |||
Viable bacterial preparations | |||||||
ORLADEYO | 959 | 1,107 | 147 | 15.4 | |||
Plasma kallikrein inhibitor | |||||||
Others | 730 | 677 | (53) | (7.3) | |||
Total | 4,113 | 4,665 | 552 | 13.4 |
- In-houseproducts
(References) Sales and ratio of in-house products
(Millions of Yen) | FY2022 | FY2023 | Change | Change (%) |
First nine months | First nine months | |||
A | B | B-A | (B-A)/A | |
Sales of in-house products | 18,598 | 20,845 | 2,246 | 12.1 |
Ratio of in-house product sales (%) | 53.1 | 53.6 | 0.5 | - |
-4-
- Research and Development
Development code 「Product Name」
Indication
Formulation/
Route of
administration
Development stage (domestic)
PhaseⅠ | PhaseⅡ | PhaseⅢ Application Approval |
Remarks
Skin disease
・Compounds for which JT has entered into a license | ||||||||
agreement with Dermavant Sciences GmbH for exclusive | ||||||||
development and commercialization in the skin disease area | ||||||||
Atopic dermatitis | Topical | Application | in Japan | |||||
・License agreement signed with JT for joint development and | ||||||||
commercialization in Japan | ||||||||
・NDA filing by JT in September, 2023 | ||||||||
・Compounds for which JT has entered into a license | ||||||||
agreement with Dermavant Sciences GmbH for exclusive | ||||||||
development and commercialization in the skin disease area | ||||||||
JTE-061 | Proriasis vulgaris | Topical | Application | in Japan | ||||
・License agreement signed with JT for joint development and | ||||||||
commercialization in Japan | ||||||||
・NDA filing by JT in September, 2023 | ||||||||
Atopic dermatitis | Topical |
in children | |
PhaseⅢ
・Compounds for which JT has entered into a license agreement with Dermavant Sciences GmbH for exclusive development and commercialization in the skin disease area in Japan
・License agreement signed with JT for joint development and commercialization in Japan
・License agreement signed with Verrica Pharmaceuticals Inc. | ||||
TO-208 | Molluscum contagiosum | Topical | PhaseⅢ | for exclusive development and commercialization in Japan |
・In-house | ||||
・Verrica Pharmaceuticals Inc., the development code: VP-102
Allergens
TO-203
「MITICURE® House
Dust Mite Sublingual
Tablets」
House dust mite induced allergic asthma (Allergen Immunotherapy)
Sublingual tablet
PhaseⅡ/Ⅲ
(Study completed※)
・License agreement signed with ALK for providing exclusive development and sales rights in Japan
・In-house
※Examining the future development policy
Update since the previous announcement on July 31,2023:
・JTE-061 for the indication of atopic dermatitis in children has entered into the clinical stage(PhaseⅢ) in Japan in August 2023.(previous announcement:Development stage「PhaseⅡ」)
・JTE-061 NDA filing for the indication of Atopic dermatitis and Proriasis Vulgaris by JT in September 2023.(previous announcement:Development stage「PhaseⅢ」)
Additional Information
・In January 2023, Torii entered into a licence agreement with Nogra Pharma Limited(Nogra) for an exclusive licence in Japan to develop and commercialize NAC-GED-0507,a treatment drug for acne vulgaris developed by Nogra.
Torii and its parent company, JT (specifically, the pharmaceutical division of the company) each leverage their own pharmaceutical product and service strengths. Torii is primarily responsible for manufacturing and marketing functions, while the parent company is responsible for research and development functions. For the clinical research and development of JT, please refer to the following company's website.
https://www.jt.com/investors/results/S_information/pharmaceuticals/index.html
-5-
III Financial Forecasts for the FY2023
The forecasts for the FY2023 have been changed from the previous forecasts announced at the first six months of FY2023 financial results announcement on July 31, 2023.
- R&D expenses fluctuate significantly due to aggressive business investments for medium-/long-term growth. For this reason, Torii sets operating income before deduction of R&D expenses as a numerical income indicator in the medium- term management plan.
- Statement of Income
FY2023 | FY2023 | Change | ||||||
(Millions of Yen) | Previous | Revised | Change | FY2022 | Change | |||
(%) | ||||||||
forecast | forecast | |||||||
A | B | B-A | C | B-C | (B-C)/C | |||
Net sales | 52,700 | 54,000 | 1,300 | 48,896 | 5,103 | 10.4 | ||
Sales of products | 52,400 | 53,700 | 1,300 | 48,563 | 5,136 | 10.6 | ||
Renal disease and hemodialysis | 11,170 | 11,970 | 800 | 12,013 | (43) | (0.4) | ||
Skin disease | 13,540 | 13,980 | 440 | 12,391 | 1,588 | 12.8 | ||
Allergens | 21,500 | 21,440 | (60) | 18,499 | 2,940 | 15.9 | ||
Other | 6,190 | 6,310 | 120 | 5,658 | 651 | 11.5 | ||
Other sales | 300 | 300 | - | 332 | (32) | (9.9) | ||
Cost of sales | 28,300 | 29,300 | 1,000 | 25,516 | 3,783 | 14.8 | ||
Gross profit | 24,400 | 24,700 | 300 | 23,379 | 1,320 | 5.6 | ||
SG&A | 20,300 | 20,200 | (100) | 17,839 | 2,360 | 13.2 | ||
R&D expenses | 3,530 | 3,600 | 70 | 1,661 | 1,938 | 116.7 | ||
Others | 16,770 | 16,600 | (170) | 16,177 | 422 | 2.6 | ||
Operating income | 4,100 | 4,500 | 400 | 5,540 | (1,040) | (18.8) | ||
Operating income before | ※ | 7,630 | 8,100 | 470 | 7,201 | 898 | 12.5 | |
deduction of R&D expenses | ||||||||
Ordinary income | 4,400 | 4,700 | 300 | 5,537 | (837) | (15.1) | ||
Net income | 3,100 | 3,400 | 300 | 3,944 | (544) | (13.8) | ||
(Reference) Ratio to net sales | ||||||||
FY2023 | FY2023 | |||||||
(%) | Previous | Revised | Change | FY2022 | Change | |||
forecast | forecast | |||||||
A | B | B-A | C | B-C | ||||
Cost of sales | 53.7 | 54.3 | 0.6 | 52.2 | 2.1 | |||
SG&A | 38.5 | 37.4 | (1.1) | 36.5 | 0.9 | |||
R&D expenses | 6.7 | 6.7 | 0.0 | 3.4 | 3.3 | |||
Operating income | 7.8 | 8.3 | 0.5 | 11.3 | (3.0) | |||
Operating income before | ※ | 14.5 | 15.0 | 0.5 | 14.7 | 0.3 | ||
deduction of R&D expenses | ||||||||
Ordinary income | 8.3 | 8.7 | 0.4 | 11.3 | (2.6) | |||
Net income | 5.9 | 6.3 | 0.4 | 8.1 | (1.8) |
-6-
【Factors in increase/decrease compared with the previous forecast for the FY2023】
Operating income (¥4,500 million : Increase ¥400 million)
- Despite an increase in the cost of sales, operating income are revised upward due to sales of Riona and ANTEBATE exceeding previous forecasts.
(Millions of yen)
6,000
4,500
3,000
1,500
0
+1,300 | (1,000) | +170 | ||||
(70) | ||||||
5,540
4,100 | 4,500 |
FY2023 | Net sales | Cost of sales | R&D expenses | Others | FY2023 | (FY2022) |
Previous forecast | Revised forecast |
Major factors in increase/decrease (Rounded down to the nearest 0.1 billion yen) | |||
Net sales | Renal disease | : | Increase ¥0.8 billion in sales Riona Increase ¥ 0.6 billion (increase in sales quantity) |
and hemodialysis | |||
Skin disease | : | Increase ¥0.4 billion in sales ANTEBATE Increase ¥0.4 billion(increase in sales quantity) | |
Allergens | : Decrease ¥0.0 billion in sales | ||
Other | : | Increase ¥0.1 billion in sales BIO-THREE Increase ¥0.1 billion (increase in sales quantity) | |
Cost of sales | : Increase in sales quantity | ||
Increase due to the effect of foreign exchange rates | |||
Increase in purchasing unit price | |||
Others | : | Decrease in sales promotion expenses |
Ordinary income (¥4,700 million : Increase ¥300 million)
Non-operating expenses:Increase in foreign exchange losses on trade payables etc. due to yen depreciation. | +125 million |
Net income (¥3,400 million :Increase ¥300 million)
None
(Reference)
Operating income before deduction of R&D expenses (¥8,100 million : Increase 470 million)
(Millions of yen)
10,000
7,500
5,000
2,500
0
+1,300 | (1,000) | +170 | ||
7,630 | 8,100 | |
7,201 | ||
FY2023 | Net sales | Cost of sales | Others | FY2023 | (FY2022) |
Previous forecast | Revised forecast |
-7-
② Sales of Products
FY2023 | FY2023 | ||||||||
(Millions of Yen) | Previous | Revised | Change | FY2022 | Change | Change(%) | |||
forecast | forecast | ||||||||
A | B | B-A | C | B-C | (B-C)/C | ||||
Sales of Products | 52,400 | 53,700 | 1,300 | 48,563 | 5,136 | 10.6 | |||
[Renal disease and hemodialysis] | |||||||||
Riona | 6,920 | 7,610 | 690 | 6,939 | 670 | 9.7 | |||
Agent for hyperphosphatemia, Iron-deficiency anemia | |||||||||
REMITCH | 2,670 | 2,730 | 60 | 3,536 | (806) | (22.8) | |||
Oral anti-pruritus agent | |||||||||
KAYEXALATE | ※ | 1,040 | 1,050 | 10 | 1,230 | (180) | (14.7) | ||
Agent for hyperkalemia | |||||||||
Others | 540 | 580 | 40 | 306 | 273 | 89.3 | |||
Total | 11,170 | 11,970 | 800 | 12,013 | (43) | (0.4) | |||
[Skin disease] | |||||||||
CORECTIM | 7,160 | 7,230 | 70 | 5,469 | 1,760 | 32.2 | |||
Topical Janus kinase (JAK) inhibitor | |||||||||
ANTEBATE | ※ | 3,940 | 4,370 | 430 | 3,995 | 374 | 9.4 | ||
Topical corticosteroid | |||||||||
LOCOID | ※ | 1,400 | 1,420 | 20 | 1,476 | (56) | (3.8) | ||
Topical corticosteroid | |||||||||
ZEFNART | 1,040 | 960 | (80) | 1,091 | (131) | (12.1) | |||
Topical antifungal agent | |||||||||
Others | - | - | - | 358 | (358) | (100.0) | |||
Total | 13,540 | 13,980 | 440 | 12,391 | 1,588 | 12.8 | |||
[Allergens] | |||||||||
CEDARCURE | ※ | 11,230 | 11,170 | (60) | 9,608 | 1,561 | 16.3 | ||
Japanese cedar pollinosis (Allergen Immunotherapy) | |||||||||
MITICURE | ※ | 10,070 | 10,090 | 20 | 8,694 | 1,395 | 16.0 | ||
House dust mite allergy (Allergen Immunotherapy) | |||||||||
Others | 200 | 180 | (20) | 196 | (16) | (8.6) | |||
Total | 21,500 | 21,440 | (60) | 18,499 | 2,940 | 15.9 | |||
[Other] | |||||||||
BIO-THREE | 3,800 | 3,900 | 100 | 3,361 | 538 | 16.0 | |||
Viable bacterial preparations | |||||||||
ORLADEYO | 1,500 | 1,500 | - | 1,313 | 186 | 14.2 | |||
Plasma kallikrein inhibitor | |||||||||
Others | 890 | 910 | 20 | 983 | (73) | (7.5) | |||
Total | 6,190 | 6,310 | 120 | 5,658 | 651 | 11.5 |
- In-houseproducts
(References) Sales and ratio of in-house products
FY2023 | FY2023 | ||||||
(Millions of Yen) | Previous | Revised | Change | FY2022 | Change | Change(%) | |
forecast | forecast | ||||||
A | B | B-A | C | B-C | (B-C)/C | ||
Sales of in-house products | 28,600 | 29,000 | 400 | 25,933 | 3,066 | 11.8 | |
Ratio of in-house product sales | (%) | 54.6 | 54.0 | (0.6) | 53.4 | 0.6 | - |
-8-
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
TORII Pharmaceutical Co. Ltd. published this content on 30 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 October 2023 08:15:42 UTC.